ArticleF1000Research2026
In-house designed Multiplex Real-Time PCR Assay Developed for Epstein - Barr virus and Cytomegalovirus DNA detection in Pooled Blood Samples from Iraqi blood donors.
Article in F1000Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The problem of transmissible human herpesvirus infections through blood donation has not been completely resolved by serological testing due to issues such as delayed in seroconversion or false-negative results. This study aimed to develop a cost-effective, In-house designed multiplex real-time PCR assay for the simultaneous detection of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) DNA in pooled blood donor samples. Methods: A total of 1000 whole-blood samples were collected from apparently healthy Iraqi blood donors and pooled into mini pools 10(MP10) i.e. 100 MP10 tested by a commercial CMV and EBV multiplex- qPCR detection kit; then retested by In-house designed multiplex qPCR. Fifteen patients who were positive for CMV and fifteen for EBV were considered as positive groups and fifteen healthy individuals as negative groups used to estimate the validity and feasibility of the In-house designed kit. Results: Blood donors who tested by the commercial kit were 42% MP10 positive for EBV and 4% positive for CMV while the In-house designed multiplex qPCR results were 40% and 6% for EBV and CMV, respectively. The specificity and sensitivity of the In-house designed kit for the detection of CMV were 97.92% (95% CI 92.6 to 99.7), 100% (95% CI 39.7 to 100), for EBV were 100% (95% CI 93.84 to100.00) and 95.24 % (95% CI 83.84 to 99.42), respectively. Conclusion: The rate of EBV was high within Iraqi blood donors while the CMV was moderately low and the In-house designed multiplex qPCR was sensitive and specific for CMV and EBV DNA detection at a much lower cost than that of the commercial, about 10% of the commercial cost. Such a cost-effective and sensitive test is crucial in reducing blood transfusion-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.